Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma

Junna Oba, Takeshi Nakahara, Sayaka Hayashida, Makiko Kido, Lining Xie, Masakazu Takahara, Hiroshi Uchi, Shogo Miyazaki, Takeru Abe, Akihito Hagihara, Yoichi Moroi, Masutaka Furue

    Research output: Contribution to journalArticle

    23 Citations (Scopus)

    Abstract

    Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

    Original languageEnglish
    Pages (from-to)1152-1160
    Number of pages9
    JournalJournal of the American Academy of Dermatology
    Volume65
    Issue number6
    DOIs
    Publication statusPublished - 2011 Dec

    Fingerprint

    Melanoma
    Neoplasms
    Survival
    Tumor-Infiltrating Lymphocytes
    Pigmented Nevus
    Nevus
    Tumor Biomarkers
    Proportional Hazards Models
    Paraffin
    Sample Size
    Formaldehyde
    Multivariate Analysis
    Neoplasm Metastasis

    Keywords

    • Breslow thickness
    • CD10
    • immunohistochemistry
    • malignant melanoma
    • melanoma-specific survival
    • prognosis
    • tumor progression

    ASJC Scopus subject areas

    • Dermatology

    Cite this

    Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. / Oba, Junna; Nakahara, Takeshi; Hayashida, Sayaka; Kido, Makiko; Xie, Lining; Takahara, Masakazu; Uchi, Hiroshi; Miyazaki, Shogo; Abe, Takeru; Hagihara, Akihito; Moroi, Yoichi; Furue, Masutaka.

    In: Journal of the American Academy of Dermatology, Vol. 65, No. 6, 12.2011, p. 1152-1160.

    Research output: Contribution to journalArticle

    Oba, J, Nakahara, T, Hayashida, S, Kido, M, Xie, L, Takahara, M, Uchi, H, Miyazaki, S, Abe, T, Hagihara, A, Moroi, Y & Furue, M 2011, 'Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma', Journal of the American Academy of Dermatology, vol. 65, no. 6, pp. 1152-1160. https://doi.org/10.1016/j.jaad.2010.10.019
    Oba, Junna ; Nakahara, Takeshi ; Hayashida, Sayaka ; Kido, Makiko ; Xie, Lining ; Takahara, Masakazu ; Uchi, Hiroshi ; Miyazaki, Shogo ; Abe, Takeru ; Hagihara, Akihito ; Moroi, Yoichi ; Furue, Masutaka. / Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. In: Journal of the American Academy of Dermatology. 2011 ; Vol. 65, No. 6. pp. 1152-1160.
    @article{2e45918c5f4a4be1b5d13bf3c5ff113e,
    title = "Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma",
    abstract = "Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53{\%}) of primary MM expressed CD10, compared with 15 of 20 cases (75{\%}) of metastatic MM and only 4 of 40 cases (10{\%}) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.",
    keywords = "Breslow thickness, CD10, immunohistochemistry, malignant melanoma, melanoma-specific survival, prognosis, tumor progression",
    author = "Junna Oba and Takeshi Nakahara and Sayaka Hayashida and Makiko Kido and Lining Xie and Masakazu Takahara and Hiroshi Uchi and Shogo Miyazaki and Takeru Abe and Akihito Hagihara and Yoichi Moroi and Masutaka Furue",
    year = "2011",
    month = "12",
    doi = "10.1016/j.jaad.2010.10.019",
    language = "English",
    volume = "65",
    pages = "1152--1160",
    journal = "Journal of the American Academy of Dermatology",
    issn = "0190-9622",
    publisher = "Mosby Inc.",
    number = "6",

    }

    TY - JOUR

    T1 - Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma

    AU - Oba, Junna

    AU - Nakahara, Takeshi

    AU - Hayashida, Sayaka

    AU - Kido, Makiko

    AU - Xie, Lining

    AU - Takahara, Masakazu

    AU - Uchi, Hiroshi

    AU - Miyazaki, Shogo

    AU - Abe, Takeru

    AU - Hagihara, Akihito

    AU - Moroi, Yoichi

    AU - Furue, Masutaka

    PY - 2011/12

    Y1 - 2011/12

    N2 - Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

    AB - Background: CD10 expression in malignant melanoma (MM) has been reported to increase according to tumor progression and metastasis; however, its association with patient outcome has not been clarified. Objective: We examined the immunohistochemical expression of CD10 in MM to determine whether or not it could serve as a marker for tumor progression and prognosis. Methods: A total of 64 formalin-fixed, paraffin-embedded samples of primary MM were immunostained for CD10. Similarly, 40 samples of melanocytic nevus and 20 of metastatic MM were analyzed for comparison. The following clinicopathologic variables were evaluated: age, gender, histologic type, tumor site, Breslow thickness, Clark level, the presence or absence of ulceration and tumor-infiltrating lymphocytes, and survival. Statistical analyses were performed to assess for associations. Several parameters were analyzed for survival using the Kaplan-Meier method and Cox proportional hazards model. Results: Immunohistochemical analysis revealed that 34 of 64 cases (53%) of primary MM expressed CD10, compared with 15 of 20 cases (75%) of metastatic MM and only 4 of 40 cases (10%) of nevus. There was a significant positive relationship between CD10 expression and Breslow thickness, Clark level, and ulceration. Univariate analysis revealed 4 significant factors for shorter survival periods: CD10 expression, high Breslow thickness, high Clark level, and the presence of ulceration (P <.01 each). In multivariate analysis, CD10 expression was revealed to be a statistically significant and independent prognostic factor. Limitations: The major limitation was the small sample size. Conclusion: CD10 expression may serve as a progression marker and can predict unfavorable prognosis in patients with MM.

    KW - Breslow thickness

    KW - CD10

    KW - immunohistochemistry

    KW - malignant melanoma

    KW - melanoma-specific survival

    KW - prognosis

    KW - tumor progression

    UR - http://www.scopus.com/inward/record.url?scp=81155131257&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=81155131257&partnerID=8YFLogxK

    U2 - 10.1016/j.jaad.2010.10.019

    DO - 10.1016/j.jaad.2010.10.019

    M3 - Article

    VL - 65

    SP - 1152

    EP - 1160

    JO - Journal of the American Academy of Dermatology

    JF - Journal of the American Academy of Dermatology

    SN - 0190-9622

    IS - 6

    ER -